Flexible Dosing of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Initial Results From the Real-World–Simulating Expanded Access Protocol Study, JADE REAL. J of Skin. 2025;9(6):s618. doi:10.25251/t4rkzz84